PET-Adapted Salvage Therapy Achieves Negativity in Hodgkin Lymphoma

Share this content:

the Cancer Therapy Advisor take:

According to a new study published in the journal The Lancet Oncology, researchers have found that PET-adapted sequential salvage therapy with brentuximab followed by augmented ifosfamide, carboplatin, and etoposide (augICE) could optimize the chance of cure after high-dose therapy and autologous stem-cell transplant (HDT/ASCT) in patients with relapsed and refractory Hodgkin lymphoma.

For this open-label, single-center, phase 2 study, researchers enrolled 46 patients with relapsed or refractory Hodgkin lymphoma who had failed one previous doxorubicin-containing regimen. Patients received brentuximab vedotin 1.2mg/kg IV on days 1, 8, and 15 for two 28-day cycles, followed by a PET scan.

Patients who achieved a Deauville score of 1 or 2 proceeded directly to HDT/ASCT, while those with PET abnormalities received two cycles of augICE before consideration for HDT/ASCT. Results showed that 69% of the 32 evaluable patients who received augICE were PET-negative in addition to the 12 patients who were PET-negative after brentuximab treatment. All 44 patients who completed the treatment protocol proceeded to received HDT/ASCT.

The results demonstrate that PET-adapted sequential salvage therapy with brentuximab vedotin followed by augICE resulted in a high proportion of patients achieving PET-negativity.

Mogamulizumab Offers Glimmer of Hope for Relapsed T-cell Lymphomas
PET-adapted sequential salvage therapy with brentuximab could optimize chance of cure in relapsed and refractory Hodgkin lymphoma.
In this study, the authors assessed the feasibility and activity of PET-adapted salvage therapy with brentuximab vedotin, followed by augmented ifosfamide, carboplatin, and etoposide (ICE).
READ FULL ARTICLE From Mdlinx

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs